США - англійська - NLM (National Library of Medicine)

caraco pharmaceutical laboratories, ltd. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - indications and usage: ticlopidine hydrochloride tablets usp are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see boxed warning and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). contraindications: the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic an

США - англійська - NLM (National Library of Medicine)

eon labs, inc. - ticlopidine hydrochloride (unii: a1l4914fmf) (ticlopidine - unii:om90zuw7m1) - ticlopidine hydrochloride 250 mg - ticlopidine hydrochloride tablets are indicated: - to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (ttp), neutropenia/agranulocytosis and aplastic anemia (see box warning  and warnings ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. - as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see clinical trials ). the use of ticlopidine is contraindicated in the following conditions: - hypersensitivity to the drug - presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either ttp or aplastic anemia - presence of a hemostatic disorder or active

США - англійська - NLM (National Library of Medicine)

general injectables & vaccines, inc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 0.4 mg in 1 ml - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology, adjunctive use in septic shock). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known to occur.

США - англійська - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 0.4 mg in 1 ml - naloxone hydrochloride injection, usp is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids, including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride injection, usp is also indicated for diagnosis of suspected or known acute opioid overdosage. naloxone hydrochloride injection, usp may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology; adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients in naloxone hydrochloride injection. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist

США - англійська - NLM (National Library of Medicine)

cardinal health - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 0.4 mg in 1 ml - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology, adjunctive use in septic shock). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known to occur.

США - англійська - NLM (National Library of Medicine)

state of florida doh central pharmacy - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the us

США - англійська - NLM (National Library of Medicine)

stat rx usa llc - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the u

США - англійська - NLM (National Library of Medicine)

physicians total care, inc. - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - loperamide hydrochloride 2 mg - loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. loperamide hydrochloride capsules are contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. loperamide hydrochloride is contraindicated in patients with abdominal pain in the absence of diarrhea. loperamide hydrochloride is not recommended in infants below 24 months of age. loperamide hydrochloride should not be used as the primary therapy: - in patients with acute dysentery, which is characterized by blood in stools and high fever, - in patients with acute ulcerative colitis, - in patients with bacterial enterocolitis caused by invasive organisms including salmonella, shigella, and campylobacter, - in patients with pseudomembranous colitis associated with the u

США - англійська - NLM (National Library of Medicine)

somerset therapeutics, llc - naloxone hydrochloride (unii: f850569pqr) (naloxone - unii:36b82amq7n) - naloxone hydrochloride 0.4 mg in 1 ml - naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol, and cyclazocine. naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see clinical pharmacology; adjunctive use in septic shock ). naloxone hydrochloride injection is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients contained in the formulation. naloxone hydrochloride injection is an opioid antagonist. physical dependence associated with the use of naloxone hydrochloride injection has not been reported. tolerance to the opioid antagonist effect of naloxone is not known to occur

США - англійська - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - diphenoxylate hydrochloride (unii: w24od7yw48) (diphenoxylate - unii:73312p173g), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - diphenoxylate hydrochloride 2.5 mg - diphenoxylate hydrochloride is effective as adjunctive therapy in the management of diarrhea. diphenoxylate hydrochloride is contraindicated in patients with: - known hypersensitivity to diphenoxylate or atropine. - obstructive jaundice. - diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria. diphenoxylate hydrochloride is classified as a schedule v controlled substance by federal regulation. diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. in doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. at high doses it exhibits codeine-like subjective effects. the dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. the insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-